APOE and Alzheimer disease: Given that the E4 carriers showed the worst clinicopathological phenotypes that positively correlated with the extent of cerebrovascular abnormalities, we consider that these molecular mechanisms identified herein may provide tractable cerebrovascular specific targets for disease modifying strategies in AD, particularly for subjects carrying the high risk APOE4 genotype.